COMMUNIQUÉS West-GlobeNewswire

BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
04/03/2026
BASEL, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose- [...]
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
04/03/2026
Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant [...]
Response to attacks against Carbios and its executives
04/03/2026
Clermont-Ferrand (France), March 4, 2026 (8:45 a.m. CET). Carbios (Euronext Growth Paris : ALCRB) denounces the destabilization operation to which it has been subjected for several months and formally contests all [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
04/03/2026
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March [...]
Réaction aux attaques visant Carbios et ses dirigeants
04/03/2026
Clermont-Ferrand (France), 4 mars 2026 (08h45 CET). Carbios (Euronext Growth Paris : ALCRB) dénonce la campagne de déstabilisation dont elle fait l’objet depuis plusieurs mois et conteste formellement l’ensemble des [...]
Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy
04/03/2026
Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and progressive soft-tissue [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
AudiLeaf Ear Health Claims Evaluated: 2026 Report Examines Ingredients, Proprietary Blend Dosing, and What Consumers Should Verify Before Buying
04/03/2026
A 2026 informational consumer evaluation of AudiLeaf's ear health marketing claims, proprietary herbal blend ingredient research context, pricing structure, and what to verify before purchasing Aurora, CO, March 03, [...]
DermaFix Nail Fungus Treatment Gel Claims Evaluated in 2026 Market Report Covering Tea Tree Oil Research, Penetration Technology Positioning, and Pricing Transparency
04/03/2026
An informational industry analysis examining ingredient-level research, marketing positioning trends, regulatory context, and publicly listed pricing structures in the topical nail fungus category Sheridan, WY, March 03 [...]
Male Power XL "Black Elixir" Claims Evaluated: 2026 Report Examines Ingredient Research, Proprietary Blend Transparency, and What Men Should Verify Before Buying
04/03/2026
A 2026 informational consumer report evaluating Male Power XL's "black elixir" marketing language, ingredient research context, proprietary blend limitations, pricing and policy terms shown on the official site, and [...]
MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify
04/03/2026
Informational 2026 consumer report examining MemoTril brain supplement ingredients, cognitive support marketing claims, ingredient research context, pricing disclosures, and what consumers should verify before [...]
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
03/03/2026
Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic [...]
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
03/03/2026
CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 28 février 2026
03/03/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 28 février 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
03/03/2026
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the [...]
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
03/03/2026
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
03/03/2026
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/03/2026
SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Pages